View Item 

Show simple item record

Clinical and Molecular Findings After Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal Data
dc.contributor.authorKeyes-Elstein, Lynette
dc.contributor.authorPinckney, Ashley
dc.contributor.authorGoldmuntz, Ellen
dc.contributor.authorWelch, Beverly
dc.contributor.authorFranks, Jennifer M.
dc.contributor.authorMartyanov, Viktor
dc.contributor.authorWood, Tammara A.
dc.contributor.authorCrofford, Leslie
dc.contributor.authorMayes, Maureen
dc.contributor.authorMcSweeney, Peter
dc.contributor.authorNash, Richard
dc.contributor.authorGeorges, George
dc.contributor.authorCsuka, M. E.
dc.contributor.authorSimms, Robert
dc.contributor.authorFurst, Daniel
dc.contributor.authorKhanna, Dinesh
dc.contributor.authorClair, E. William St
dc.contributor.authorWhitfield, Michael L.
dc.contributor.authorSullivan, Keith M.
dc.date.accessioned2023-03-03T21:09:50Z
dc.date.available2024-03-03 16:09:49en
dc.date.available2023-03-03T21:09:50Z
dc.date.issued2023-02
dc.identifier.citationKeyes-Elstein, Lynette ; Pinckney, Ashley; Goldmuntz, Ellen; Welch, Beverly; Franks, Jennifer M.; Martyanov, Viktor; Wood, Tammara A.; Crofford, Leslie; Mayes, Maureen; McSweeney, Peter; Nash, Richard; Georges, George; Csuka, M. E.; Simms, Robert; Furst, Daniel; Khanna, Dinesh; Clair, E. William St; Whitfield, Michael L.; Sullivan, Keith M. (2023). "Clinical and Molecular Findings After Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal Data." Arthritis Care & Research 75(2): 307-316.
dc.identifier.issn2151-464X
dc.identifier.issn2151-4658
dc.identifier.urihttps://hdl.handle.net/2027.42/175915
dc.publisherWiley Periodicals, Inc.
dc.titleClinical and Molecular Findings After Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal Data
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelGeriatrics
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/175915/1/acr24785_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/175915/2/acr24785.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/175915/3/acr24785-sup-0001-Disclosureform.pdf
dc.identifier.doi10.1002/acr.24785
dc.identifier.sourceArthritis Care & Research
dc.identifier.citedreferenceFielding S, Ogbuagu A, Sivasubramaniam S, et al. Reporting and dealing with missing quality of life data in RCTs: has the picture changed in the last decade? Qual Life Res 2016; 25: 2977 – 83.
dc.identifier.citedreferenceBell ML, Fiero M, Horton NJ, et al. Handling missing data in RCTs;a review of the top medical journals. BMC Med Res Methodol 2014; 14: 118 – 25.
dc.identifier.citedreferenceIbrahim JG, Chu H, Chen MH, et al. Missing data in clinical studies: issues and methods. J Clin Oncol 2012; 30: 3297 – 303.
dc.identifier.citedreferenceZhang Y, Florez ID, Lozano LE, et al. A systematic survey on reporting and methods for handling missing participant data for continuous outcomes in randomized controlled trials. J Clin Epidemiol 2017; 88: 57 – 66.
dc.identifier.citedreferenceVonesh EF. Generalized linear and nonlinear models for correlated data: theory and applications using SAS®. Cary (NC): SAS Institute Inc; 2012.
dc.identifier.citedreferenceWhitfield ML, Finlay DR, Murray JL, et al. Systemic and cell type-specific gene expressions in scleroderma skin. PNAS 2003; 100: 12319 – 24.
dc.identifier.citedreferenceFranks JM, Martyanov V, Cai G, et al. A machine learning classifier for assigning individual patients with systemic sclerosis to intrinsic molecular subsets. Arthritis Rheumatol 2019; 71: 1701 – 10.
dc.identifier.citedreferenceMilano A, Pendergrass SA, Sargent JL, et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One 2008; 3: e2696.
dc.identifier.citedreferencePendergrass SA, Lemaire R, Francis IP, et al. Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies. J Invest Dermatol 2012; 132: 1363 – 73.
dc.identifier.citedreferenceHinchcliff M, Huang CC, Wood TA, et al. Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis. J Invest Dermatol 2013; 133: 1979 – 89.
dc.identifier.citedreferenceMahoney JM, Taroni J, Martyanov V, et al. Systems level analysis of systemic sclerosis shows a network of immune and profibrotic pathways connected with genetic polymorphisms. PLoS Comput Biol 2015; 11: e1004005.
dc.identifier.citedreferenceSkaug B, Khanna D, Swindell WR, et al. Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. Ann Rheum Dis 2020; 79: 379 – 86.
dc.identifier.citedreferenceKhanna D, Spino C, Johnson S, et al. Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial. Arthritis Rheumatol 2020; 72: 125 – 36.
dc.identifier.citedreferenceTaroni JN, Martyanov V, Huang CC, et al. Molecular characterization of systemic sclerosis esophageal pathology identifies inflammatory and proliferative signatures. Arthritis Res Ther 2015; 17: 194.
dc.identifier.citedreferenceTaroni JN, Greene CS, Martyanov V, et al. A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis. Genome Med 2017; 9: 27.
dc.identifier.citedreferenceFranks JM, Martyanov V, Wang Y, et al. Machine learning predicts stem cell transplant response in severe scleroderma. Ann Rheum Dis 2020; 79: 1608 – 15.
dc.identifier.citedreferenceGauthier J, Wu QV, Gooley TA. Cubic splines to model relationships between continuous variables and outcomes: a guide for clinicians. Bone Marrow Transplant 2020; 55: 675 – 80.
dc.identifier.citedreferenceBaron G, Boutron I, Giraudeau B, et al. Violation of intent-to-treat principle and rate of missing data in superiority trials assessing structural outcomes in rheumatic diseases. Arthritis Rheumatol 2005; 54: 1858 – 65.
dc.identifier.citedreferenceWong WK, Boscardin WJ, Postlethwaite AE, et al. Handling missing data issues in clinical trials for rheumatic diseases. Contemp Clin Trials 2011; 1 – 9.
dc.identifier.citedreferenceFleming TR. Addressing missing data in clinical trials. Ann Intern Med 2011; 154: 1113 – 17.
dc.identifier.citedreferenceAkl EA, Briel M, You JJ, et al. Potential impact on estimated treatment effects of information lost to follow-up in randomized controlled trials (LOST-IT): systematic review. Brit Med J 2012; 344: e2809.
dc.identifier.citedreferenceSymmons DP. Epidemiology research in rheumatology-progress and pitfalls. Nat Rev Rheumatol 2015; 11: 631 – 8.
dc.identifier.citedreferenceKim M, Merrill JT, Wang C, et al. SLE clinical trials: impact of missing data on estimating treatment effects. Lupus Sci Med 2019; 6: e000348.
dc.identifier.citedreferenceBudhiraja P, Kalot M, El Alayli E, et al. Reporting and handling of missing participant data in systematic reviews of kidney transplant studies. Transplantation 2021; 105: 1708 – 17.
dc.identifier.citedreferenceKahale LA, Khamis AM, Diab B, et al. Potential impact of missing outcome data on treatment effects in systematic reviews: imputation study. Brit Med J 2020; 370: m2898.
dc.identifier.citedreferenceIbrahim F, Tom BD, Scott DL, et al. A systematic review of randomized controlled trials in rheumatoid arthritis: the reporting and handling of missing data in composite outcomes. Trials 2016; 17: 272 – 80.
dc.identifier.citedreferenceBell ML, Kenward MG, Fairclough DL, et al. Differential dropout and bias in RCs: when it matters and when it may not. Brit Med J 2013; 346: e8668.
dc.identifier.citedreferencePowney M, Williamson P, Kirkham J, et al. A review of the handling of missing longitudinal outcome data in clinical trials. Trials 2014; 15: 237.
dc.identifier.citedreferenceZhang Y, Alyass A, Vanniyasingam T, et al. A systematic survey of the methods literature on the reporting quality and optimal methods of handling participants with missing outcome data for continuous outcomes in randomized controlled trials. J Clin Epidemiol 2017; 889: 67 – 80.
dc.identifier.citedreferenceBurt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomized phase 2 trial. Lancet 2011; 378: 498 – 506.
dc.identifier.citedreferenceVan Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014; 311: 2490 – 8.
dc.identifier.citedreferenceHinchcliff M, Toledo DM, Taroni JN, et al. Mycophenolate mofetil treatment of systemic sclerosis reduces myeloid cell numbers and attenuates the inflammatory gene signature in skin. J Invest Dermatol 2018; 138: 1301 – 10.
dc.identifier.citedreferenceMayes MD, Lacey JV Jr, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003; 48: 2246 – 55.
dc.identifier.citedreferenceElhai M, Meune C, Avouac J, et al. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2012; 51: 1017 – 26.
dc.identifier.citedreferenceNihtyanova SI, Schreiber BE, Ong VH, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol 2014; 66: 1625 – 35.
dc.identifier.citedreferenceSullivan KM, Goldmuntz EA, Keyes-Elstein L, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med 2018; 378: 35 – 47.
dc.identifier.citedreferenceAssassi S, Wang X, Chen G, et al. Myeloablation followed by autologous stem cell transplantation normalizes systemic sclerosis molecular signatures. Ann Rheum Dis 2019; 78: 1371 – 8.
dc.identifier.citedreferenceLittle RJ, D’Agostino R, Cohen ML, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med 2012; 367: 1355 – 60.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
acr24785_am.pdf
Size:
895.7KB
Format:
PDF
View/Open
Name:
acr24785.pdf
Size:
1.594MB
Format:
PDF
View/Open
Name:
acr24785-sup-0001-Disclosurefo ...
Size:
1.164MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.